Company: SION
Filing Date: 2025-06-13
Form Type: 8-K
Source: 0002036042-25-000018
Chunk: 0

Company: Sionna Therapeutics, Inc.
Filing Date: 2025-06-13
Form: 8-K
Item: Item 5.07
Chunk 0
---
Item 5.07 Submission of Matters to a Vote of Security Holders.

On June 12, 2025, Sionna Therapeutics, Inc. (the "Company") held its Annual Meeting of Stockholders, at which a quorum was present. There were 44,124,394 shares of the Company's common stock outstanding as of the record date of April 15, 2025.

The following are the voting results for the proposals considered and voted upon at the meeting, which are described in detail in the Company's Definitive Proxy Statement filed with the Securities and Exchange Commission on April 29, 2025.

1. To elect three nominees as Class I directors: Joshua Resnick, M. D., M. B. A., Bruce Booth, D. Phil., and Lucian Iancovici, M. D., each to hold office until the Company's Annual Meeting of Stockholders in 2028.

  Nominee                Votes For      Votes Withheld      Broker Non-Votes  
 ──────────────────────────────────────────────────────────────────────────────
  Joshua Resnick        42,090,273             602,898               496,255  
  Bruce Booth           42,076,029             617,142               496,255  
  Lucian Iancovici      42,090,273             602,898               496,255  

2. To ratify the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025.

   Votes For      Votes Against      Abstentions  
 ──────────────────────────────────────────────────
  43,189,421                  0                5  

Based on the foregoing votes, each of the nominees was elected as a Class I director and the appointment of Deloitte & Touche LLP was ratified.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

                                       Sionna Therapeutics, Inc.  
  Date: June 13, 2025      By:         /s/ Jennifer Fitzpatrick   
                           Name:       Jennifer Fitzpatrick       
                           Title:      Chief Legal Officer